These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22226 related articles for article (PubMed ID: 19232159)

  • 1. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
    Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
    Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.
    Shoji S; Nishizawa Y; Tabata T; Emoto M; Morita A; Goto H; Ishimaura E; Inoue T; Inaba M; Miki T
    Miner Electrolyte Metab; 1995; 21(1-3):223-8. PubMed ID: 7565454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
    Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
    Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone disease in uremic patients: advances in PTH suppression.
    Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
    J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium balance and intact PTH variations during haemodiafiltration.
    Argilés A; Mion CM
    Nephrol Dial Transplant; 1995 Nov; 10(11):2083-9. PubMed ID: 8643172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 1112.